4.7 Article

Rare Nonsynonymous Variants in Alpha-4 Nicotinic Acetylcholine Receptor Gene Protect Against Nicotine Dependence

Journal

BIOLOGICAL PSYCHIATRY
Volume 70, Issue 6, Pages 528-536

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2011.04.017

Keywords

CHRNA4; deep sequencing; imaging genetics; nicotine dependence; nonsynonymous; rare variants

Funding

  1. National Institute of Health [R01 DA12690, R01 DA12849, R01 AA11330, R01 AA017535, K01 DA020651, R01 DA015577, 2P50-AA012870, K05 AA017435, R01 DA030976]
  2. Vetrans Affairs (VA) VISN1 MIRECC
  3. VA Alcohol Research Center
  4. Clinical Neuroscience Division of the VA National Center for Posttraumatic Stress Disorder
  5. Alkermes
  6. GlaxoSmithKline
  7. Gilead
  8. Merck
  9. ACNP Alcohol Clinical Trials Initiative (ACTIVE)
  10. Janssen Research Foundation

Ask authors/readers for more resources

Background: Several studies report association of alpha-4 nicotinic acetylcholine receptors (encoded by CHRNA4) with nicotine dependence (ND). A meta-analysis of genomewide linkage studies for ND implicated a single chromosomal region, which includes CHRNA4, as genome-wide significant. Methods: After establishing that common variants are unlikely to completely account for this linkage, we investigated the distribution of CHRNA4 rare variants by sequencing the coding exons and flanking intronic regions of CHRNA4 in 209 European American (EA) ND cases and 183 EA control subjects. Because most of the rare variants that we detected (and all nonsynonymous changes) were in Exon 5, we sequenced Exon 5 in an additional 1000 ND cases and 1000 non-ND comparison subjects, both of which included equal numbers of EAs and African Americans. Results: Comparison subjects had a higher frequency of rare nonsynonymous variants in the Exon 5 region (encoding the large intercellular loop of the alpha 4 subunit; Fisher's Exact Test p = .009; association test p = .009, odds ratio = .43; weighted-sum method p = .014), indicating a protective effect against ND. Considering data from the two stages combined and only nonsynonymous variants predicted to alter protein function, the association was stronger (Fisher's Exact Test p = .005; association test p = .008, odds ratio = .29; weighted-sum method p = .005). Single-photon emission computed tomography imaging results were consistent with functionality. Conclusions: CHRNA4 functional rare variants may reduce ND risk. This is the first demonstration that rare functional variants at a candidate locus protect against substance dependence to our knowledge, suggesting a novel mechanism of substance dependence heritability that is potentially of general importance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available